The Latest in Psoriatic Arthritis

Bimekizumab Rapidly Improves Patient-Reported Outcomes in PsA

October 21, 2024

Psoriatic Arthritis

Rapid Improvement in Disease Activity With Ixekizumab vs IL-23 and IL-12/23 Inhibitors in PsA

October 21, 2024

Psoriatic Arthritis

Rheumatology News

FDA Approves Ustekinumab Biosimilar Otulfi

October 3, 2024

Rheumatology News

Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential Risks

September 27, 2024

Commentary: PsA Targeted Therapy Trials, October 2024

September 27, 2024

Psoriatic Arthritis

Rheumatology News

Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial Spondyloarthritis

September 24, 2024

Rheumatology News

Rheumatology Clinic Interventions for Smoking, Blood Pressure ‘Make a Big Difference’

September 18, 2024

Presence of Central Sensitization Should Be Considered During PsA Treatment

September 18, 2024

Psoriatic Arthritis

Bimekizumab Shows Long-Term Safety and Efficacy in Biologic-Naive and TNFi-IR PsA Patients

September 18, 2024

Psoriatic Arthritis

Guselkumab Shows Early and Sustained Efficacy in PsA

September 18, 2024

Psoriatic Arthritis

Potential Predictive Biomarkers for Biologic Treatment Response in PsA

September 18, 2024

Psoriatic Arthritis

PsA Patients Initiating bDMARD Face High Risk for Interstitial Lung Disease

September 18, 2024

Psoriatic Arthritis

Bimekizumab Bests Risankizumab in PsA

September 18, 2024

Psoriatic Arthritis

DMARD-Naive and DMARD-Failure PsA Patients Show Similar Imaging Profile

September 18, 2024

Psoriatic Arthritis

Risankizumab Safe for Long-Term Use in PsA

September 18, 2024

Psoriatic Arthritis